en · de · es · fr · pt
ipamorelin-notes.peptides4088.com › Data › Analytical Characterisation And Storage — Research Overview

Analytical Characterisation And Storage — Research Overview

By Editorial Desk · published 2025-12-28 · last reviewed 2026-01-20 · Data

The short version of GHS-R1a fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.

Analytical Characterisation and Storage

The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.

Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.

Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.

Handling Storage And Analytical Control

Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Ipamorelin at a glance

PropertyValueNotes
Primary purity methodReversed-phase HPLCC18 column, water-acetonitrile gradient
Detection wavelength214 nm, optionally 280 nmAmide backbone and aromatic side chains
Identity confirmationElectrospray ionisation mass spectrometryDeconvoluted mass compared with theory
Storage of solid-20 °C or lower, dry and darkStability depends on residual moisture
Storage in solution2-8 °C, short termFreeze-thaw cycling avoided

Ipamorelin Background and Pharmacology

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

Related pages on this site

背景与分子特征

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

Further detail

In microbiology, colonial morphology refers to the visual appearance of bacterial or fungal colonies on an agar plate. Examining colonial morphology is the first step in the identification of an unknown microbe. The systematic assessment of the colonies' appearance, focusing on aspects like size, shape, colour, opacity, and consistency, provides clues to the identity of the organism, allowing microbiologists to select appropriate tests to provide a definitive identification.

Polycarbodiimides can also be used as crosslinkers for aqueous resins, such as polyurethane dispersions or acrylic dispersion. Here the polycarbodiimide reacts with carboxylic acids, whose functional groups are often present in such aqueous resins, to form N-acyl urea. The result is the formation of covalent bonds between the polymer chains, making them crosslinked.

Atherosclerosis is a pattern of the disease arteriosclerosis, characterized by the development of atheromatous plaques in the walls of arteries. This is a chronic inflammatory disease involving many different cell types and is driven by elevated blood levels of cholesterol, primarily LDL. These lesions lead to narrowing of the arteries. At the onset, there are usually no symptoms, but if they develop, symptoms generally begin around middle age. In severe cases, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney disorders, depending on the body part(s) in which the affected arteries are located. The exact cause of atherosclerosis is unknown and is proposed to be multifactorial. Risk factors include abnormal cholesterol levels, elevated levels of inflammatory biomarkers, high blood pressure, diabetes, smoking (both active and passive smoking), obesity, genetic factors, family history, lifestyle habits, and an unhealthy diet. Plaque is made up of fat, cholesterol, immune cells, calcium, and other substances found in the blood. The narrowing of arteries limits the flow of oxygen-rich blood to parts of the body. Diagnosis is based upon a physical exam, electrocardiogram, and exercise stress test, among others, depending on the affected artery or arteries. Prevention guidelines include eating a healthy diet, exercising, not smoking, and maintaining a normal body weight.

ATP + H2O + oligopeptide [oligopeptide - binding protein][side 1] = ADP + phosphate + oligopeptide [side 2] + [oligopeptide - binding protein][side 1] 7.4.2.7 ABC-type alpha-factor-pheromone transporter The enzyme appears in viruses and cellular organisms characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. Does not undergo phosphorylation during the transport process. A yeast enzyme that exports the α-factor sex pheromone. ATP + H2O + alpha factor [side 1] = ADP + phosphate + alpha factor [side 2] 7.4.2.8 ABC-type protein-secreting ATPase The expected taxonomic range for this enzyme is: Archaea, Bacteria. A non-phosphorylated, non-ABC (ATP-binding cassette) ATPase that is involved in protein transport. ATP + H2O + cellular protein [side 1] = ADP + phosphate + cellular protein [side 2] 7.4.2.9 ABC-type dipeptide transporter The enzyme appears in viruses and cellular organisms. ATP-binding cassette (ABC) type transporter, characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the uptake of dipeptides and tripeptides.

Sources: en.wikipedia.org

Supporting material

=== Membership pharmacy === The Membership Pharmacy Model is an emerging practice area that structurally departs from traditional volume-based pharmacy by shifting the primary revenue source from drug sales to recurring patient membership fees. This model centers its practice on providing medications at or near their Actual Acquisition Cost (AAC) and prioritizing medication adherence and value-based patient outcomes over dispensing volume. The resulting financial incentives align the pharmacy's success with patient benefit, encouraging the efficient use of medications rather than maximizing the number of prescriptions filled. The core function of a membership pharmacy model involves two primary operational shifts. First, the pharmacy treats prescription fulfillment as an expense, incentivizing efficiency. Second, it shifts its inventory model from "Just-in-Case" (JIC) to a highly efficient "Just-in-Time" (JIT) approach. This is achieved by systematically coordinating all member refills to a single, periodic dispensing date. This efficiency enables the pharmacy to reduce operational costs, key to the model of treating prescription fulfillment, as an expense, rather than a profit center.

=== Medicare === Inhorn was also involved in the implementation of Medicare, which was enacted in 1965 as a new federal program to provide health insurance to citizens over age 65. As the largest health care program ever undertaken by the U.S. government, Medicare required quality assurance practices for all facets of its healthcare provision. Soon, another bill was passed called the Clinical Laboratory Improvement Act of 1967, requiring QA practices in the delivery of laboratory testing. To develop the regulations for CLIA-67, a meeting was held at the Communicable Disease Center, CDC (later renamed the Centers for Disease Control and Prevention). The Social Security Administration was also involved, and charged with defining personnel standards for laboratories, such as Director, Supervisor, or Technologist, based on education and experience. Inhorn was selected in 1973 to chair the committee to develop an exam for cytotechnologists who had on-the-job Pap smear training, but not the formal university education required by the new Medicare-related QA standards. Inhorn was also selected to chair the Proficiency Testing Committee, which had the responsibility to fashion a program that would define the frequency of testing, the number of samples, controls, standards, scoring methodology, passing grades, and requirements to continue provision of services for each specialty. Furthermore, Inhorn was selected to help the CDC, given that there were few established standards and methods to use in assessment of medical laboratory performance.

==== Regulation ==== Enzymes can be either activated or inhibited by other molecules. For example, the end product(s) of a metabolic pathway are often inhibitors for one of the first enzymes of the pathway (usually the first irreversible step, called committed step), thus regulating the amount of end product made by the pathways. Such a regulatory mechanism is called a negative feedback mechanism, because the amount of the end product produced is regulated by its own concentration. Negative feedback mechanism can effectively adjust the rate of synthesis of intermediate metabolites according to the demands of the cells. This helps with effective allocations of materials and energy economy, and it prevents the excess manufacture of end products. Like other homeostatic devices, the control of enzymatic action helps to maintain a stable internal environment in living organisms.

== History == Martin Freund and (Jakob) Edmund Speyer of the University of Frankfurt in Germany published the first synthesis of oxycodone from thebaine in 1916. When Freund died, in 1920, Speyer wrote his obituary for the German Chemical Society. Speyer, born to a Jewish family in Frankfurt am Main in 1878, became a victim of the Holocaust. He died on 5 May 1942, the second day of deportations from the Lodz Ghetto; his death was noted in the ghetto's chronicle. The first clinical use of the drug was documented in 1917, the year after it was first developed. It was first introduced to the U.S. market in May 1939. In early 1928, Merck introduced a combination product containing scopolamine, oxycodone, and ephedrine under the German initials for the ingredients SEE, which was later renamed Scophedal (SCOpolamine, ePHEDrine, and eukodAL) in 1942. It was last manufactured in 1987 but can be compounded. This combination is essentially an oxycodone analogue of the morphine-based "twilight sleep", with ephedrine added to reduce circulatory and respiratory effects. The drug became known as the "Miracle Drug of the 1930s" in Continental Europe and elsewhere and it was the Wehrmacht's choice for a battlefield analgesic for a time. The drug was expressly designed to provide what the patent application and package insert referred to as "very deep analgesia and profound and intense euphoria" as well as tranquillisation and anterograde amnesia useful for surgery and battlefield wounding cases.

AGE HMGB1 (Amphoterin) S100A12 (EN-RAGE) S100B S100A7 (psoriasin) but not highly homologous S100A7A (koebnerisin) S100P S100A8/A9 complex referred to as calprotectin Amyloid-β-protein Mac-1 Phosphatidylserine. S100A4

Sources: en.wikipedia.org

Supporting material

== Works cited == Bose, Romen (2010). The End of the War: Singapore's Liberation and the Aftermath of the Second World War. Singapore: Marshall Cavendish. ISBN 978-981-261-066-9. Legg, Frank (1965). The Gordon Bennett Story: From Gallipoli to Singapore. Sydney, New South Wales: Angus & Robertson. OCLC 3193299. Miksic, John N. (2013). Singapore & the Silk Road of the Sea, 1300–1800. Singapore: NUS Press. ISBN 978-9971-69-558-3. Smith, Colin (2006). Singapore Burning: Heroism and Surrender in World War II. Penguin military history. London: Penguin Books. ISBN 978-0-14-101036-6. Toland, John (1970). The Rising Sun: The Decline and Fall of the Japanese Empire, 1936–1945. New York, NY: Random House. LCCN 77-117669. OL 25646706M. Wigmore, Lionel (1957). The Japanese Thrust. Canberra: Australian War Memorial.

=== Veterinary === Deslorelin is used in veterinary medicine. One commercial form of deslorelin acetate is marketed by Peptech with the brand name Ovuplant. Another form is available in the United States, Sucromate Equine, which was FDA-approved for use in horses in November 2010. This is manufactured by Thorne BioScience LLC and was introduced to the United States market following the withdrawal of Ovuplant. The deslorelin products are currently approved for use in veterinary medicine and to promote ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion. Suprelorin is a slowly releasing deslorelin implant used for chemical castration of dogs and ferrets. It is marketed by Virbac. Deslorelin is also used to treat benign prostate hyperplasia in dogs. It is also used to treat pet parrots suffering from chronic egg laying behavior.

=== Philanthropy === Morea serves as the captain and midfielder of the All Stars Football Club, a celebrity football team that participates in matches to raise funds for charitable causes. He played in a high-profile charity cricket match organized by the IIFA Foundation at Headingley Carnegie Stadium in Leeds, England, on 8 June 2007. The event featured a star-studded Indian celebrity team—including Virat Kohli, Kapil Dev, Vivek Oberoi, Ajay Devgn, Shilpa Shetty, Sunny Deol, and many others—competing against a UK celebrity team and the match benefited the IIFA Foundation's charitable causes. Morea attended a charity football match for the Salman Khan's Being Human Foundation in Mumbai on 15 August 2009. Dino joined Salman Khan, Aamir Khan, Amitabh Bachchan, and others for a blood donation camp in Bandra, Mumbai on 15 August 2010. In March 2013, he participated in a match to support the Magic Funds Organisation, which works with underprivileged children. In 2016, he became associated with Pet Fed, an event platform for pets, joining as an investor and supporter.

Radioactive primordial nuclides found in the Earth are residues from ancient supernova explosions that occurred before the formation of the Solar System. They are the fraction of radionuclides that survived from that time, through the formation of the primordial solar nebula, through planet accretion, and up to the present time. The naturally occurring short-lived radiogenic radionuclides found in today's rocks, are the daughters of those radioactive primordial nuclides. Another minor source of naturally occurring radioactive nuclides are cosmogenic nuclides, that are formed by cosmic ray bombardment of material in the Earth's atmosphere or crust. The decay of the radionuclides in rocks of the Earth's mantle and crust contribute significantly to Earth's internal heat budget.

Small integral membrane protein 20 (SMIM20) is a protein that in humans is encoded by the SMIM20 gene. SMIM20 acts as a prohormone to the peptide hormone phoenixin (PNX) which was discovered for the first time in 2013 in rodent sensory ganglia. Two alternate cleavage sites within SMIM20 results in two different phoenixin products, Phoenixin-14 (PNX-14) and Phoenixin-20 (PNX-20). In the study of the evolution of nervous systems, SMIM20 together with NUCB2 have been found to have deep homology across all lineages that preceded creatures with central nervous systems, bilaterians, cnidarians, ctenophores, and sponges as well as in choanoflagellates.

Sources: en.wikipedia.org

Frequently asked questions

How is peptide purity usually reported?

Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.

Why is mass spectrometry used alongside chromatography?

Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.

What happens to the peptide in solution over time?

Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.

How is ipamorelin purity measured?

Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.

Network